Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01106651 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 716
- Enrollment target
NCT01106651: Completed Phase 3 study, sponsored by Janssen Research & Development.
NCT01106651 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 716 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01106651, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 716 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control on their current diabetes treatment regimen.
Primary Outcome
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
Interventions
- DRUG Placebo
- DRUG Canagliflozin 100 mg
- DRUG Canagliflozin 300 mg
- DRUG Antihyperglycemic agent(s)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 716 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
What the finished NCT01106651 record still lists
NCT01106651 is an interventional study that assigns participants to a tested intervention. The registered 716 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01106651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01106651 about?
NCT01106651 is a clinical study titled "A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control on their current diabetes treatment regimen.
What is the current status of trial NCT01106651?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 716 participants. The study started on 2010-06. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01106651?
The interventions under investigation include: Placebo (DRUG), Canagliflozin 100 mg (DRUG), Canagliflozin 300 mg (DRUG), Antihyperglycemic agent(s) (DRUG).
Who is sponsoring clinical trial NCT01106651?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01106651's enrollment target sits among peer trials
716 498th of 2000 higher than 1,503 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04680000 · 716 participants · NA
Chronic Pain Management In Primary Care Using Behavioral Health Consultants
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NCT06758401 · 714 participants · Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- NCT04916327 · 720 participants · NA
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia